Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022–2023

• Published in: The Journal of infectious diseases Vol. 229; no. 6; pp. 1830 - 1835
• Main Authors: Andreev, Konstantin, Jones, Jeremy C, Seiler, Patrick, Kandeil, Ahmed, Turner, Jasmine C M, Barman, Subrata, Rubrum, Adam M, Webby, Richard J, Govorkova, Elena A
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 14.06.2024
• Subjects: Acids, Carbocyclic; Animals; Antiviral agents; Antiviral Agents - pharmacology; Antiviral drugs; Avian flu; Birds - virology; Brief Report; Cyclopentanes - pharmacology; Dibenzothiepins - pharmacology; Drug Resistance, Viral - genetics; Exo-a-sialidase; Genotype; Guanidines - pharmacology; Humans; Influenza A; Influenza A Virus, H5N1 Subtype - drug effects; Influenza A Virus, H5N1 Subtype - genetics; Influenza in Birds - virology; Influenza, Human - drug therapy; Influenza, Human - virology; Microbial Sensitivity Tests; Morpholines - pharmacology; Neuraminidase - antagonists & inhibitors; Neuraminidase - genetics; Pyridones - pharmacology; RNA-Dependent RNA Polymerase - genetics; Susceptibility; Triazines - pharmacology; Viral Proteins - genetics; Viral Proteins - metabolism; Viruses; Zanamivir; Zanamivir - pharmacology; H5N1; avian influenza; neuraminidase inhibitors; baloxavir; resistance

Abstract The antiviral susceptibility of currently circulating (2022–2023) highly pathogenic avian influenza (HPAI) A(H5N1) viruses was assessed by genotypic and phenotypic approaches. The frequency was low for neuraminidase (NA) and polymerase acidic (PA) substitutions associated with reduced inhib...